Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Breast Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 06/30/2015
Study Completion Date: 04/30/2021
This randomized phase III trial studies how will doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple negative breast cancer.